Table 3.

Occurrence of hepatocellular carcinoma (HCC) after direct-acting antiviral (DAA) treatment and sustained virological response (SVR) in patients without previous HCC history [21, 23, 26, 28–30, 32–35]

Authors (year) [references]	Total SVR patients (n)	Observation periods (months post-DAA initiation)	Patients with HCC occurrence [n (%)]	Annual incidence of HCC (%/year)
Conti et al. (2016) [21]	254	9	7 (2.7)	3.60
Cardoso et al. (2017) [23]	54	18	4 (7.4)	4.93
Mettke et al. (2017) [26]	158	17.5	6 (3.8)	2.61
Nagata et al. (2017) [28]	652	21.6	7 (1.1)	0.61
Kanwal et al. (2017) [29]	19,518	15.8	183 (0.9)	0.68
Ioannou et al. (2017) [30]	19,909	18	280 (1.4)	0.93
Ooka et al. (2018) [32]	769	15	17 (2.2)	1.76
Reddy et al. (2018) [33]	893	36	16 (1.8)	0.60
Ogawa et al. (2018) [34]	1523	17	20 (1.3)	0.92
Calvaruso et al. (2018) [35]	2140	14	64 (3.0)	2.57
Total	45,870	18.2 (9–36)	604 (1.3)	1.92 (0.60–4.93)

n number